Replies to post #176622 on Anavex Life Sciences Corp (AVXL)

[tredenwater2]

Also why is (according to USPTO Public Pair btw. an effing clunky and slow website) the patent not assigned to Anavex, but instead with Anavex as the applicant indicating that Cecchi is part of Anavex.

Investor perhaps there is an announcement forthcoming about a partnership between Neuronetrix, Anavex, Ariana, and who knows maybe even Harald Hampel with new method of testing for ALZ after all this is HH's specialty. Perhaps together they have designed an early Alz. detection test for all to use.


Excerpts from Dr. Hampel's bio:

"A member of the Scientific Advisory Board and an internationally recognized expert on Alzheimer’s and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France. The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer’s Disease (IM2A), a reference center for Alzheimer’s and other neurodegenerative diseases, and affiliated with a leading neuroscience institution, the Brain and Spine Institute (ICM), as well as the Department of Neurology at the Pitié-Salpétrière University Hospital. He has conducted more than 50 clinical trials over the past 20 years and has developed international programs focused on Alzheimer’s therapy, diagnosis and the development of biological and imaging biomarkers, including his current work as AXA-UPMC Chair, which aims to improve early detection at the preclinical ‘silent stage’ before the onset of any clinical signs and symptoms. After a post-doctoral fellowship focused on structural and functional neuroimaging of the healthy aging and Alzheimer’s disease brain at the NIH/NIA Laboratory of Neurosciences in Bethesda, MD, "

Tred

[nidan7500]

Huh, well I read the patent as about the process of dose-testing-dosing.etc till done..in iterative steps customized to each patient using the AI tool to measure/verify biomarker results, thereby assessing efficacy of treatment. I will admit it is not clear but that is my read. My prior life biases may have influenced me but I was also seeing this patent as defining a step by step protocol, using both Neuronetrix tool and A2-73 sequentially also thinking Precision Medicine links . We'll see. Thanks again.

[F1ash]

Digressing slightly - This extended activation period of the Sigma-1 Receptor perhaps holds an answer to why DPZ co-administration in smaller doses is ok despite its higher affinity e.g. DPZ is metabolised quicker and leaves the biological system well before A19-144

What is the basis for your above statement?


“The elimination half-life of Donepezil is about 70 hours, and the mean apparent plasma clearance (Cl/F) is 0.13 to 0.19 L/hr/kg. Following multiple dose administration, Donepezil accumulates in plasma by 4 to 7 fold, and steady state is reached within 15 days. The steady state volume of distribution is 12 to 16 L/kg

https://www.drugs.com/pro/donepezil.html